| Literature DB >> 35361858 |
Barbara Kot1, Małgorzata Piechota2, Andrzej Jakubczak3, Magdalena Gryzińska3, Małgorzata Witeska2, Agata Grużewska4, Katarzyna Baran2, Paulina Denkiewicz2.
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is responsible for hard-to-treat infections. The presence of 19 virulence genes in 120 MRSA isolates obtained from hospitalized patients and genetic relationships of these isolates were investigated. The eno (100%) and ebps (93.3%) genes encoding laminin- and elastin binding proteins, respectively, were ubiquitous. Other adhesion genes: fib (77.5%), fnbB (41.6%), bbp (40.8%), cna (30.8%) encoding proteins binding fibrinogen, fibronectin, bone sialoprotein and collagen, respectively, and map/eap (62.5%), encoding Eap, were also frequent. The etB and etD genes, encoding exfoliative toxins, were present in 15.6% and 12.5% isolates, respectively. The splA, splE and sspA, encoding serine protease were detected in 100%, 70.8% and 94.2% isolates, respectively. The tst gene, encoding toxic shock syndrome toxin-1 was found in 75% isolates. The cna, map/eap and tst genes were the most common in wound isolates and much less common in blood isolates. We identified 45 different spa types, t003 (21.7%) and t008 (18.8%) being the most common. The t003 was the most frequent among isolates from the respiratory tract (35.5%), while t008 in blood isolates (40%). Identification of virulence factors of MRSA is important for evaluation of pathogen transmission rate and disease development.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35361858 PMCID: PMC8971418 DOI: 10.1038/s41598-022-09517-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
The prevalence of virulence-associated genes in MRSA isolates from patients hospitalized in 2015–2017.
| Virulence-associated genes | No. (%) of isolates with gene |
|---|---|
| 37 (30.8) | |
| 93 (77.5) | |
| 50 (41.6) | |
| 112 (93.3) | |
| 49 (40.8) | |
| 120 (100) | |
| 75 (62.5) | |
| 0 (0.0) | |
| 18 (15.0) | |
| 15 (12.5) | |
| 120 (100) | |
| 85 (70.8) | |
| 113 (94.2) | |
| 30 (25.0) | |
| 5 (4.2) | |
| 3 (2.5) | |
| 11 (9.2) | |
| 1 (0.8) | |
| 90 (75.0) | |
Figure 1The groups of genes encoding adhesins, proteases and superantigenic toxins in MRSA isolated from patients hospitalized in 2015–2017 created based on the cluster analysis. fnbB, bbp, cna, fib, ebpS, eno—genes encoding adhesins such as fibronectin B-, bone sialoprotein-, collagen-, fibrinogen-, elastin-, laminin-binding proteins, respectively; map—gene encoding Eap (extracellular adherence protein); etA, etB, etD—genes encoding exfoliative toxins; splA, sspA, splE—genes encoding serine proteases; sea, seb, sec, sed, see—genes encoding the enterotoxins A to E; tst—gene encoding the toxic shock syndrome toxin-1.
The most frequent virulotypes in MRSA isolates from different clinical specimens.
| Virulotypes | Source (No. of isolates) | No. of isolates (%) | |
|---|---|---|---|
| Respiratory tract (6) | t003 (4), t17775 (1), t1842 (1) | 8 (6.7) | |
| Nose (2) | t003 (1), t901 (1) | ||
| Wound (2) | t2944, t899 | 3 (2.5) | |
| Anus (1) | t5224 | ||
| Respiratory tract (2) | t008 (2) | 3 (2.5) | |
| Anus (1) | t6665 |
The prevalence of virulence-associated genes in MRSA isolates from different clinical specimens.
| Genes | Source of isolation | |||||
|---|---|---|---|---|---|---|
| Respiratory tract, n = 48 (%) | Wound, n = 30 (%) | Anus, n = 15 (%) | Blood, n = 11 (%) | Nose, n = 8 (%) | Other, n = 8 (%) | |
| 9 (18.8) | 16 (53.3) | 5 (33.3) | 1 (9.1) | 3 (37.5) | 3 (37.5) | |
| 39 (81.0) | 21 (70.0) | 15 (100) | 9 (81.8) | 7 (87.5) | 6 (75.0) | |
| 19 (40.0) | 15 (50.0) | 5 (33.3) | 4 (36.4) | 2 (25.0) | 5 (62.5) | |
| 44 (92.0) | 29 (96.7) | 15 (100) | 11 (100) | 7(87.5) | 6 (75.0) | |
| 15 (31.0) | 16 (53.3) | 9 (60.0) | 4 (36.4) | 2 (25.0) | 3 (37.5) | |
| 48 (100) | 30 (100) | 15 (100) | 11 (100) | 8 (100) | 8 (100) | |
| 30 (63.0) | 22 (73.3) | 10 (66.6) | 4 (36.4) | 5 (62.5) | 4 (50.0) | |
| 0 | 0 | 0 | 0 | 0 | 0 | |
| 10 (20.8) | 5 (16.7) | 0 | 1 (9.1) | 1 (12.5) | 1 (12.5) | |
| 9 (18.8) | 4 (13.0) | 3 (20.0) | 0 | 0 | 2 (25.0) | |
| 48 (100) | 30 (100) | 15 (100) | 11 (100) | 8 (100) | 8 (100) | |
| 33 (68.8) | 24 (80.0) | 11 (73.3) | 5 (45.5) | 5 (62.5) | 7 (87.5) | |
| 45 (93.8) | 28 (93.0) | 14 (93.3) | 11 (100) | 7 (87.5) | 8 (100) | |
| 14 (29.2) | 2 (6.7) | 4 (26.6) | 1 (9.1) | 2(25.0) | 2 (25.0) | |
| 1 (2.0) | 1 (3.3) | 0 | 0 | 0 | 1 (12.5) | |
| 2 (4.2) | 1 (3.3) | 0 | 0 | 0 | 0 | |
| 5 (10.4) | 3 (10.0) | 1 (6.6) | 2 (18.2) | 0 | 0 | |
| 1 (2.0) | 0 | 0 | 0 | 0 | 0 | |
| 33 (68.8) | 27 (90.0) | 11 (73.3) | 6 (54.5) | 8 (100) | 6 (75.0) | |
Occurrence of the spa types among MRSA isolates from different clinical specimens.
| Source of isolation | |||||||
|---|---|---|---|---|---|---|---|
| Respiratory tract, n = 45 (%) | Wound, n = 23 (%) | Anus, n = 13 (%) | Blood, n = 10 (%) | Nose, n = 8 (%) | Other, n = 7 (%) | Total n = 106 (%) | |
| t003 | 16 (35.5) | 2 (8.7) | 3 (23.1) | – | 1 (7.7) | 1 (14.3) | 23 (21.7) |
| t008 | 10 (22.2) | 2 (8.7) | – | 4 (40) | 2 (25) | 2 (28.6) | 20 (18.8) |
| t4474 | 2 (4.4) | 2 (8.7) | 1 (7.7) | – | – | – | 5 (4.7) |
| t5224 | – | 2 (8.7) | 3 (23.1) | – | – | – | 5 (4.7) |
| t3592 | – | 1 (4.3) | – | – | 1 (7.7) | 1 (14.3) | 3 (2.8) |
| t1079 | 2 (4.4) | – | – | – | – | – | 2 (1.9) |
| t1227 | – | 2 (8.7) | – | – | – | – | 2 (1.9) |
| t276 | – | 1 (4.3) | 1 (7.7) | – | – | – | 2 (1.9) |
| t012 | 1 (2.2) | 1 (4.3) | – | – | – | – | 2 (1.9) |
| t1806 | 1 (2.2) | 1 (4.3) | – | – | – | – | 2 (1.9) |
| t11766 | – | – | 2 (15.4) | – | – | – | 2 (1.9) |
| t899 | – | 1 (4.3) | 1 (7.7) | – | – | – | 2 (1.9) |
| t3069 | – | – | – | 2 (20) | – | – | 2 (1.9) |
| t8746 | 2 (4.4) | – | – | – | – | – | 2 (1.9) |
| t901 | – | – | – | – | 2 (25) | – | 2 (1.9) |
| t837 | 1 (2.2) | – | – | – | – | – | 1 (0.9) |
| t6447 | 1 (2.2) | – | – | – | – | – | 1 (0.9) |
| t627 | 1 (2.2) | – | – | – | – | – | 1 (0.9) |
| t1777 | 1 (2.2) | – | – | – | – | – | 1 (0.9) |
| t2379 | 1 (2.2) | – | – | – | – | – | 1 (0.9) |
| t034 | 1 (2.2) | – | – | – | – | – | 1 (0.9) |
| t6401 | 1 (2.2) | – | – | – | – | – | 1 (0.9) |
| t4657 | 1 (2.2) | – | – | – | – | – | 1 (0.9) |
| t6506 | 1 (2.2) | – | – | – | – | – | 1 (0.9) |
| t7784 | – | 1 (4.3) | – | – | – | – | 1 (0.9) |
| t437 | – | 1 (4.3) | – | – | – | – | 1 (0.9) |
| t16934 | – | 1 (4.3) | – | – | – | – | 1 (0.9) |
| t026 | – | 1 (4.3) | – | – | – | – | 1 (0.9) |
| t037 | – | 1 (4.3) | – | – | – | – | 1 (0.9) |
| t2944 | – | 1 (4.3) | – | – | – | – | 1 (0.9) |
| t870 | – | 1 (4.3) | – | – | – | – | 1 (0.9) |
| t6447 | – | – | 1 (7.7) | – | – | – | 1 (0.9) |
| t6665 | – | – | 1 (7.7) | – | – | – | 1 (0.9) |
| t11792 | – | – | – | 1 (10) | – | – | 1 (0.9) |
| t12426 | – | – | – | 1 (10) | – | – | 1 (0.9) |
| t5655 | – | – | – | 1 (10) | – | – | 1 (0.9) |
| t014 | – | – | – | 1 (10) | – | – | 1 (0.9) |
| t1842 | 1 (2.2) | – | – | – | – | – | 1 (0.9) |
| t1282 | 1 (2.2) | – | – | – | – | – | 1 (0.9) |
| t018 | – | – | – | – | 1 (7.7) | – | 1 (0.9) |
| t1446 | – | – | – | – | 1 (7.7) | – | 1 (0.9) |
| t002 | – | 1 (4.3) | – | – | – | – | 1 (0.9) |
| t12250 | – | – | – | – | – | 1 (14.3) | 1 (0.9) |
| t5160 | – | – | – | – | – | 1 (14.3) | 1 (0.9) |
| t1209 | – | – | – | – | – | 1 (14.3) | 1 (0.9) |
MRSA isolation sources.
| Isolates from hospital in: | Source of isolation | |||||
|---|---|---|---|---|---|---|
| Respiratory tract, n = 48 | Wound, n = 30 | Anus, n = 15 | Blood n = 11 | Nose, n = 8 | Other, n = 8 | |
| Siedlce (n = 83) | 36 | 20 | 10 | 9 | 6 | 2 |
| Warsaw (n = 37) | 12 | 10 | 5 | 2 | 2 | 6 |
Primers used in PCR.
| Gene | Protein | Primer sequences (5′ → 3′) | Length (bp) | References |
|---|---|---|---|---|
| Collagen binding protein | GTCAAGCAGTTATTAACACCAGAC AATCAGTAATTGCACTTTGTCCACTG | 423 | Tristan et al.[ | |
| Fibrinogen binding protein | CTACAACTACAATTGCCGTCAACAG GCTCTTGTAAGACCATTTTCTTCAC | 404 | ||
| Fibronectin binding protein A | GTGAAGTTTTAGAAGGTGGAAAGATTAG GCTCTTGTAAGACCATTTTTCTTCAC | 643 | ||
| Fibronectin binding protein B | GTAACAGCTAATGGTCGAATTGATACT CAAGTTCGATAGGAGTACTATGTTC | 524 | ||
| Elastin binding protein | CATCCAGAACCAATCGAAGAC CTTAACAGTTACATCATCATGTTTATCTTTG | 186 | ||
| Bone sialoprotein binding protein | AACTACATCTAGTACTCAACAACAG ATGTGCTTGAATAACACCATCATCT | 575 | ||
| Laminin binding protein | ACGTGCAGCAGCTGACT CAACAGCATTCTTCAGTACCTTC | 302 | ||
| Broad binding of extracellular matrix proteins | TAACATTTAATAAGAATCAA CCATTTACTGCAATTGT | 943–9 | Rohde et al.[ | |
| Exfoliative toxin A | TTGTAAAAGGACAAACAAGTGC TTCCCAATACCAACACC | 544 | Ote et al.[ | |
| Exfoliative toxin B | TTACAAGCAAAAGAATACAGCG GGAAGATTATGTTGTCCGCC | 641 | ||
| Exfoliative toxin D | ACTATCATGTATCAAGGATGGCT CTCCTTTTCCAACATGAATACC | 432 | ||
| Serine protease SplA | GCGGGTGGTACTGGTGTAGT CGTTCCTGTCGATTCAAACA | 339 | ||
| Serine protease SplE | ATGTCGTTGCAGGTATGG CCGTTTCCACCAAAGTGA | 409 | ||
| Serine V8 protease | GATGCTACGCACGGTGATCC GGTTGGTCATCGTTGGCA | 503 | ||
| Enterotoxin A | CAGCATACTATATTGTTTAAAGGC CCTCTGAACCTTCCCATC | 400 | Park et al.[ | |
| Enterotoxin B | GTATGGTGGTGTAACTGAGCA TCAATCTTCACATCTTTAGAATCA | 351 | ||
| Enterotoxin C | CTCAAGAACTAGACATAAAAGCTAGG TCAAAATCGGATTAACATTATCC | 271 | Becker et al.[ | |
| Enterotoxin D | CTAGTTTGGTAATATCTCCTTTAAACG TTAATGCTATATCTTATAGGGTAAACATC | 319 | ||
| Enterotoxin E | CAGTACCTATAGATAAAGTTAAAACAAGC TAACTTACCGTGGACCCTTC | 178 | ||
| Toxic shock syndrome toxin-1 | TTTTTTATCGTAAGCCCTTTGTTGC CACCCGTTTTATCGCTTGAA | 550 | Ote et al.[ |